Table 3 Summary of findings for MAGE reduction compared DPP-IV inhibitors to other OADs based on the GRADE approach.
Outcome | No. of Participants (studies) | Limitation | Inconsistency | Indirectness | Imprecision | Publication bias | Mean difference* (95% CI) | Quality of Evidence |
|---|---|---|---|---|---|---|---|---|
Overall | 304 (8) | No serious | No serious | No serious | No serious | Undetected | −14.61 (−19.00, −10.21) | ⊕⊕⊕⊕ High |
Compared to sulfonylurea | 279 (7) | No serious | No serious | No serious | No serious | Undetected | −14.93 (−21.60,−8.26) | ⊕⊕⊕⊕ High |
According to types of therapy | ||||||||
Stepwise addition therapy | 124 (4) | No serious | No serious | No serious | No serious | Undetected | −9.26 (−16.40, −2.11) | ⊕⊕⊕⊕ High |
Initial combination therapy | 128 (3) | No serious | Serious | No serious | No serious | Undetected | −23.36 (−30.45, −16.26) | ⊕⊕⊕◯ Moderate |
According to HbA1c | ||||||||
HbA1c ≥7.5% | 205 (5) | No serious | No serious | No serious | No serious | Undetected | −12.78 (−18.70, −6.85) | ⊕⊕⊕⊕ High |
HbA1c ≤7.5% | 99 (3) | No serious | No serious | No serious | No serious | Undetected | −16.84 (−23.39, −10.29) | ⊕⊕⊕⊕ High |
